Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England

AbstractBackgroundThe rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five months ago. However, the safety of the third (booster) dose has not been fully established yet.ObjectiveEvaluate the short-term, self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.DesignA prospective observational study, in which participants are equipped with a smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, starting seven days before the vaccination.SettingAn Israel-wide third (booster) vaccination campaign.ParticipantsA group of 1,609 (18+ years of age) recipients of at least one dose of the BNT162b2 vaccine between December 20, 2020, and September 15, 2021, out of a larger cohort of 2,912 prospective study participants. 1,344 of the participants were recipients of the third vaccine dose.MeasurementsDaily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate, heart rate variability and blood oxygen saturation level were continuously measured by Garmin Vivosmart 4 smartwatches.ResultsThe extent of systemic reactions reported following the third (booster) dose administration is similar to that reported following the second dose (p-value=0.305) and considerably greater than that reported following the first dose (p-value<0.001). Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further support this finding. Focusing on the third dose, reactions were more apparent in younger participants (p-value<0.01), in women (p-value<0.001), and in participants with no underlying medical conditions (p-value<0.001). Nevertheless, reported reactions and changes in physiological measures returned to their baseline levels within three days from inoculation with the third dose.LimitationsParticipants may not adequately represent the vaccinated population in Israel and elsewhere.ConclusionOur work further supports the safety of a third COVID-19 BNT162b2 mRNA (booster) vaccine dose from both a subjective and an objective perspective, particularly in individuals 65+ years of age and those with underlying medical conditions.Primary funding sourceEuropean Research Council (ERC) project #949850

Download Full-text

The safety and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) booster vaccine in healthy Vietnamese children

Vaccine ◽

10.1016/j.vaccine.2016.07.005 ◽

2016 ◽

Vol 34 (37) ◽

pp. 4360-4363

Author(s):

Dang Duc Anh ◽

Girish Jayadeva ◽

Sherine Kuriyakose ◽

Htay Htay Han

Keyword(s):

Booster Vaccine

Download Full-text

Febrile illness and bicytopenia within hours after tick-borne encephalitis booster vaccination

npj Vaccines ◽

10.1038/s41541-019-0152-2 ◽

2019 ◽

Vol 4 (1) ◽

Cited By ~ 1

Author(s):

Tim Bühler ◽

Noemi Boos ◽

Anne B. Leuppi-Taegtmeyer ◽

Christoph T. Berger

Keyword(s):

Systemic Reaction ◽

Booster Vaccination ◽

Febrile Illness ◽

Adverse Event Reporting ◽

Sudden Onset ◽

Review Of The Literature ◽

Booster Vaccine ◽

Tick Borne Encephalitis ◽

Reporting Systems ◽

Close Temporal Relationship

AbstractWe report the case of a 20-year-old male complaining of sudden-onset, severe headaches, fever, chills, and generalized arthralgia. He had no symptoms of a respiratory tract infection. Blood examination revealed severe leukopenia and mild to moderate thrombocytopenia. Onset of symptoms was rapid, intense, and occurred only a few hours after routine tick-borne encephalitis (TBE) booster vaccine. The question of a relationship between booster vaccine administration and the febrile illness with bicytopenia was raised. A broad range of diagnostics excluded infections and other causes for bicytopenia. Symptoms resolved within a few days, and blood counts normalized within two weeks. Due to the close temporal relationship, a transient benign bicytopenia and febrile illness as a systemic reaction to TBE vaccination was assumed. Review of the literature and adverse event reporting systems suggest that this is a very rare reaction.

Download Full-text

Maintaining Hepatitis B Protection in Immunocompromised Pediatric Rheumatology and Inflammatory Bowel Disease Patients

The Journal of Rheumatology ◽

10.3899/jrheum.200283 ◽

2020 ◽

pp. jrheum.200283

Author(s):

Najla Aljaberi ◽

Enas Ghulam ◽

Emily A. Smitherman ◽

Leslie Favier ◽

Dana M.H. Dykes ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Hepatitis B ◽

Bowel Disease ◽

Immunocompromised Patients ◽

Duration Of Treatment ◽

Hbv Vaccine ◽

Booster Vaccine ◽

Significant Difference ◽

Inflammatory Bowel ◽

Hbv Screening

Objective Hepatitis B virus (HBV) infection remains a significant public health challenge, particularly for immunocompromised patients. Our aim was to evaluate the serologic immunity in immunocompromised rheumatology and inflammatory bowel disease (IBD) patients, assess factors for serologic non-immunity and evaluate their response to one HBV booster dose. Methods Immunocompromised rheumatology and IBD patients with completed HBV screening were identified. A chart review was performed to collect demographics, clinical information, baseline HBV serology results, and serologic response to booster vaccination. Serologic nonimmunity was defined as a negative/indeterminate hepatitis B surface antibody (anti-HBs) level. Results Among 580 patients, 71% were non-immune. The highest portion of non-immune patients were 11-18 years old (p 0.004). There was no significant difference between immune and non-immune patients with regards to diagnosis (p 0.342), age at diagnosis (p 0.639), duration of treatment (p 0.069) or type of medications (p 0.080). Sixty-two percent of those who received a booster vaccine were re-screened, and most (68%) seroconverted. In those 18 years or older, only half seroconverted. Conclusion Results of this study support the benefit of HBV screening in immunosuppressed patients. Beginning at age 11 years most patients lacked serologic immunity to HBV. Seroconversion for most patients 11-18 years occurred after one booster vaccine. Thus, for immunocompromised patients without recent HBV serologic data, obtaining the HBV serology beginning at age 11 years might be considered. Those 18 years and older were least likely to seroconvert after one booster, indicating that they may benefit from receiving the three-dose HBV vaccine series.

Download Full-text